Trial Profile
A real world setting investigation of adverse events of telaprevir-based therapy in patients with and without advanced fibrosis or cirrhosis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2015
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- 18 Nov 2015 New trial record